Ocrevus (ocrelizumab) / Biogen, Roche  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

23 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ocrevus (ocrelizumab) / Roche
NCT02807285: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

No Longer Available
N/A
US
Ocrelizumab, RO4964913
Genentech, Inc.
Multiple Sclerosis
 
 
HepB20, NCT04519710: Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

Completed
N/A
60
Europe
o receive treatment with anti-CD20 (rituximab or ocrelizumab) and to be vaccinated against hepatitis B
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HBV
09/21
10/23
SEP-RR, NCT04838015: Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS

Recruiting
N/A
250
Europe
University Hospital, Strasbourg, France
Multiple Sclerosis
11/21
11/21
CPE, NCT05762003: Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

Completed
N/A
17478
RoW
interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
IMPULS Endowment Fund
Multiple Sclerosis
12/21
12/21
NCT04855617: Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis

Completed
N/A
122
US
Ocrelizumab, OCREVUS
NYU Langone Health, Genentech, Inc.
Multiple Sclerosis
10/22
10/22
NCT04640818: Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

Active, not recruiting
N/A
45
Europe
Cladribine Oral Tablet, Mavenclade, Rituximab, Mabthera, Rixathon, Ocrelizumab, Ocrevus
Claudio Gobbi, Merck AG Switzerland
Multiple Sclerosis
10/22
10/22
NCT03562975: Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

Active, not recruiting
N/A
18
US
Ocrelizumab, Ocrevus
University of South Florida, Genentech, Inc.
Multiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
02/23
12/23
NCT03396822: Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

Completed
N/A
24
US
Gadoteridol
University of Maryland, Baltimore, Genentech, Inc.
Multiple Sclerosis
05/23
05/23
NCT04843774: Vaccine-generated Immunity in Ocrelizumab-treated Patients: Longitudinal Assessments (VIOLA)

Completed
N/A
64
US
SARS-COV-2 mRNA Vaccine
NYU Langone Health
Multiple Sclerosis
04/23
04/23
NCT05627271: The 'Wearing Off' Effect of DMT

Completed
N/A
39
Europe
ocrelizumab, Ocrevus, natalizumab, Tysabri, ofatumumab, Kesimpta
Novartis Pharmaceuticals
Multiple Sclerosis
04/23
04/23
NCT03873389: Ocrelizumab Effects on the Metabolome in MS

Completed
N/A
25
US
Ocrelizumab, Ocrevus
Johns Hopkins University, Genentech, Inc.
Multiple Sclerosis
06/23
12/23
NCT04459988: Mechanistic Study of Ocrevus

Completed
N/A
35
US
Ocrelizumab, Ocrevus
University of Michigan
Multiple Sclerosis
10/22
10/22
NCT05081700: A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

Active, not recruiting
N/A
14
US
All patients in the study will be treated with ocrelizumab, OCREVUS
Providence Health & Services, Institute for Systems Biology, Genentech, Inc.
Multiple Sclerosis
12/24
12/24
NCT04874597: Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With Suppressive Capacity in MS

Active, not recruiting
N/A
30
RoW
Ocrelizumab
Dr Recai Turkoglu, Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital
Multiple Sclerosis
11/23
11/23
NCT04448977: Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI

Recruiting
N/A
60
US
Ocrevus
Kessler Foundation, Hackensack Meridian Health
Multiple Sclerosis, Relapsing-Remitting
12/24
12/24
ORATORIO-CP, NCT05974852: Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

Active, not recruiting
N/A
732
US
Ocrelizumab
State University of New York at Buffalo, Genentech, Inc.
Primary Progressive Multiple Sclerosis
11/24
09/25
ORATORIO-Cort, NCT05974839: Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ical)

Active, not recruiting
N/A
732
US
Ocrelizumab
State University of New York at Buffalo, Genentech, Inc.
Primary Progressive Multiple Sclerosis
06/24
09/25
NCT05266469: Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Recruiting
N/A
240
RoW
Ofatumumab, Ocrelizumab
Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
12/24
12/24
NCT06121349: WOE of Anti-CD20 Therapies

Recruiting
N/A
150
US
ocrelizumab, Ocrevus, ofatumumab, KESIMPTA
Novartis Pharmaceuticals
Multiple Sclerosis
02/25
02/25
NCT04458688: Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Recruiting
N/A
80
US
Observation of Ocrelizumab as Treatment in RRMS Patients, Observing Ocrelizumab Use
Wayne State University
Multiple Sclerosis, Relapsing-Remitting
07/25
12/30
MuSicalE, NCT03593590: Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

Active, not recruiting
N/A
1710
Europe, RoW
Ocrelizumab, Ocrevus
Hoffmann-La Roche
Multiple Sclerosis
07/25
07/25
TREAT-MS, NCT03500328: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

Recruiting
N/A
900
US
Natalizumab, Alemtuzumab, Ocrelizumab, Rituximab, Cladribine, Ofatumumab, Ublituximab-xiiy, Tysabri, Lemtrada, Ocrevus, Rituxan, Mavenclad, Kesimpta, Briumvi, Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod, Copaxone, Glatopa, Avonex, Betaseron, Extavia, Rebif, Plegridy, Aubagio, Tecfidera, Vumerity, Bafiertam, Gilenya, Mayzent, Zeposia, Ponvory, Tascenso
Johns Hopkins University, Patient-Centered Outcomes Research Institute, National Multiple Sclerosis Society
Multiple Sclerosis, Relapsing-Remitting
08/25
08/25
NCT05688436: A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
N/A
1178
US
Diroximel Fumarate, VUMERITY, BIIB098, Alemtuzumab, Fingolimod, Glatiramer acetate, Interferon beta, Natalizumab, Tysabri, BG00002, Ocrelizumab, Ofatumumab, Ozanimod, Peginterferon beta-1a, Ponesimod, Siponimod
Biogen
Multiple Sclerosis
01/31
01/31

Download Options